Skip to main content
Top
Published in: Virology Journal 1/2024

Open Access 01-12-2024 | Human Papillomavirus | Research

Prevalence of high and low risk HPV genotypes among vaccinated and non-vaccinated people in Tehran

Authors: Amir Gholamzad, Niloofar Khakpour, Mehrdad Hashemi, Mehrdad Gholamzad

Published in: Virology Journal | Issue 1/2024

Login to get access

Abstract

Background

Human Papillomavirus (HPV) is a prevalent STI (Sexually Transmitted Infection) that is estimated almost all sexually active Patients at some stage of their life will be infected by the virus. Although most HPV infections resolve spontaneously, some can result in health complications, such as genital warts and several types of cancer. This study analyzed the variety of HPV genotypes in females and males among the infected population.

Methods

Samples were obtained from the oral, vaginal, and genital sites of study participants and the samples underwent DNA extraction and subsequently amplified using Real-Time PCR. The recognition of high-risk (HR) and low-risk (LR) HPV genotypes was carried out using the HPV REALQUALITY RQ-Multi diagnostic kit and demographic information was analyzed alongside statistical virological data.

Results

Out of 936 samples, 324 cases (34.6%) were found to be positive for HPV, while 612 cases (65.4%) were negative. Of our participants, 70 samples of males (27.5%) and 254 samples of females (37.3%) were HPV-positive. Common genotypes included 16, 6, 11, and 18, while genotypes 59, 56, 31, 45, and 52 were also detected.

Conclusion

According to the findings of this study, a significant prevalence of HPV infection was seen in males and females, and the incidence of high-risk genotypes was more diverse in males. While the vaccine was effective in preventing some types of HPV, such as 16, 18, 6, and 11, there seems to be an increase in infections caused by other genotypes, and precautions should be taken to prevent future health problems.
Literature
1.
go back to reference Taskin MH, Nursal AF, Oruc MA, Kariptas E. Genotype distribution and prevalence of high-risk human papillomavirus infection among women in samsun province of Turkey. Asian Pac J Cancer Prev. 2022;23(7):2477–82.CrossRefPubMedPubMedCentral Taskin MH, Nursal AF, Oruc MA, Kariptas E. Genotype distribution and prevalence of high-risk human papillomavirus infection among women in samsun province of Turkey. Asian Pac J Cancer Prev. 2022;23(7):2477–82.CrossRefPubMedPubMedCentral
2.
go back to reference Krasniqi E, Barba M, Venuti A, Pizzuti L, Cappuzzo F, Landi L et al. Circulating HPV DNA in the management of Oropharyngeal and cervical cancers: current knowledge and future perspectives. J Clin Med. 2021;10(7). Krasniqi E, Barba M, Venuti A, Pizzuti L, Cappuzzo F, Landi L et al. Circulating HPV DNA in the management of Oropharyngeal and cervical cancers: current knowledge and future perspectives. J Clin Med. 2021;10(7).
3.
go back to reference Cossellu G, Fedele L, Badaoui B, Angiero F, Farronato G, Monti E, et al. Prevalence and concordance of oral and genital HPV in women positive for cervical HPV Infection and in their sexual stable partners: an Italian screening study. PLoS ONE. 2018;13(10):e0205574.CrossRefPubMedPubMedCentral Cossellu G, Fedele L, Badaoui B, Angiero F, Farronato G, Monti E, et al. Prevalence and concordance of oral and genital HPV in women positive for cervical HPV Infection and in their sexual stable partners: an Italian screening study. PLoS ONE. 2018;13(10):e0205574.CrossRefPubMedPubMedCentral
4.
go back to reference Lewis RM, Laprise JF, Gargano JW, Unger ER, Querec TD, Chesson HW, et al. Estimated prevalence and incidence of disease-associated human Papillomavirus types among 15- to 59-Year-Olds in the United States. Sex Transm Dis. 2021;48(4):273–7.CrossRefPubMedPubMedCentral Lewis RM, Laprise JF, Gargano JW, Unger ER, Querec TD, Chesson HW, et al. Estimated prevalence and incidence of disease-associated human Papillomavirus types among 15- to 59-Year-Olds in the United States. Sex Transm Dis. 2021;48(4):273–7.CrossRefPubMedPubMedCentral
6.
go back to reference Koleśnik M, Stępień E, Polz-Dacewicz M. Prevalence of human papillomavirus (HPV) in the oral cavity of a healthy population in South-Eastern Poland. Int J Environ Res Public Health. 2022;19(12):7213.CrossRefPubMedPubMedCentral Koleśnik M, Stępień E, Polz-Dacewicz M. Prevalence of human papillomavirus (HPV) in the oral cavity of a healthy population in South-Eastern Poland. Int J Environ Res Public Health. 2022;19(12):7213.CrossRefPubMedPubMedCentral
7.
go back to reference Serrano L, López AC, González SP, Palacios S, Dexeus D, Centeno-Mediavilla C, et al. Efficacy of a Coriolus versicolor-based vaginal gel in women with human papillomavirus-dependent cervical lesions: the PALOMA Study. J Low Genit Tract Dis. 2021;25(2):130–6.CrossRefPubMedPubMedCentral Serrano L, López AC, González SP, Palacios S, Dexeus D, Centeno-Mediavilla C, et al. Efficacy of a Coriolus versicolor-based vaginal gel in women with human papillomavirus-dependent cervical lesions: the PALOMA Study. J Low Genit Tract Dis. 2021;25(2):130–6.CrossRefPubMedPubMedCentral
8.
go back to reference Wilson LA, Quan AML, Bota AB, Mithani SS, Paradis M, Jardine C, et al. Newcomer knowledge, attitudes, and beliefs about human papillomavirus (HPV) vaccination. BMC Fam Pract. 2021;22(1):17.CrossRefPubMedPubMedCentral Wilson LA, Quan AML, Bota AB, Mithani SS, Paradis M, Jardine C, et al. Newcomer knowledge, attitudes, and beliefs about human papillomavirus (HPV) vaccination. BMC Fam Pract. 2021;22(1):17.CrossRefPubMedPubMedCentral
9.
go back to reference Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog. 2020;16(3):e1008376.CrossRefPubMedPubMedCentral Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog. 2020;16(3):e1008376.CrossRefPubMedPubMedCentral
10.
go back to reference Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH et al. Development of DNA vaccine targeting E6 and E7 proteins of human Papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody. mBio. 2021;12(1). Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH et al. Development of DNA vaccine targeting E6 and E7 proteins of human Papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody. mBio. 2021;12(1).
11.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef
12.
go back to reference Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399.CrossRefPubMed Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399.CrossRefPubMed
13.
go back to reference Ährlund-Richter A, Cheng L, Hu YOO, Svensson M, Pennhag AAL, Ursu RG et al. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade after the introduction of the HPV Vaccine. Front Cell Infect Microbiol. 2019;9. Ährlund-Richter A, Cheng L, Hu YOO, Svensson M, Pennhag AAL, Ursu RG et al. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade after the introduction of the HPV Vaccine. Front Cell Infect Microbiol. 2019;9.
14.
go back to reference Sadr-Momtaz S, Aftabi M, Behboudi E, Naderi M, Hashemzadeh-Omran A, Moradi A. NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice. BMC Res Notes. 2023;16(1):164.CrossRefPubMedPubMedCentral Sadr-Momtaz S, Aftabi M, Behboudi E, Naderi M, Hashemzadeh-Omran A, Moradi A. NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice. BMC Res Notes. 2023;16(1):164.CrossRefPubMedPubMedCentral
15.
go back to reference Razavi-Nikoo H, Behboudi E, Aghcheli B, Hashemi S, Moradi A. Bac to Bac system efficiency for preparing HPV type 16 virus-like particle vaccine. Arch Razi Inst. 2023;78(3):997.PubMedPubMedCentral Razavi-Nikoo H, Behboudi E, Aghcheli B, Hashemi S, Moradi A. Bac to Bac system efficiency for preparing HPV type 16 virus-like particle vaccine. Arch Razi Inst. 2023;78(3):997.PubMedPubMedCentral
16.
go back to reference Ekanayake Weeramange C, Liu Z, Hartel G, Li Y, Vasani S, Langton-Lockton J, et al. Salivary high-risk human papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck cancers. J Mol Diagn. 2021;23(10):1334–42.CrossRefPubMedPubMedCentral Ekanayake Weeramange C, Liu Z, Hartel G, Li Y, Vasani S, Langton-Lockton J, et al. Salivary high-risk human papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck cancers. J Mol Diagn. 2021;23(10):1334–42.CrossRefPubMedPubMedCentral
17.
go back to reference Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against Cancer. Vaccines (Basel). 2021;9(12). Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against Cancer. Vaccines (Basel). 2021;9(12).
18.
go back to reference Todor RD, Bratucu G, Moga MA, Candrea AN, Marceanu LG, Anastasiu CV. Challenges in the Prevention of Cervical Cancer in Romania. Int J Environ Res Public Health. 2021;18(4):1721.CrossRefPubMedPubMedCentral Todor RD, Bratucu G, Moga MA, Candrea AN, Marceanu LG, Anastasiu CV. Challenges in the Prevention of Cervical Cancer in Romania. Int J Environ Res Public Health. 2021;18(4):1721.CrossRefPubMedPubMedCentral
19.
go back to reference Hassani S, Nadji PS, Mohseni A, Rahnamaye Farzami M, Mirab Samiee S, Sadr M, Nadji SA. Evaluation frequency of human papillomavirus and its related genotypes in women of the General Population living in 11 provinces of Iran. Can J Infect Dis Med Microbiol. 2022;2022:8668557.CrossRefPubMedPubMedCentral Hassani S, Nadji PS, Mohseni A, Rahnamaye Farzami M, Mirab Samiee S, Sadr M, Nadji SA. Evaluation frequency of human papillomavirus and its related genotypes in women of the General Population living in 11 provinces of Iran. Can J Infect Dis Med Microbiol. 2022;2022:8668557.CrossRefPubMedPubMedCentral
20.
go back to reference Shen-Gunther J, Xia Q, Stacey W, Asusta HB. Molecular pap smear: validation of HPV genotype and host methylation profiles of ADCY8, CDH8, and ZNF582 as a predictor of cervical cytopathology. Front Microbiol. 2020;11:595902.CrossRefPubMedPubMedCentral Shen-Gunther J, Xia Q, Stacey W, Asusta HB. Molecular pap smear: validation of HPV genotype and host methylation profiles of ADCY8, CDH8, and ZNF582 as a predictor of cervical cytopathology. Front Microbiol. 2020;11:595902.CrossRefPubMedPubMedCentral
22.
go back to reference Olia J, Ansari M, Yaghmaei P, Ayatollahi H, Khalkhali H. Genotyping the human papillomavirus Infection in Iranian women referred to Shahid Motahari Hospital, in Urmia, with real-time polymerase chain reaction techniques. Annals of Tropical Medicine and Public Health. 2018;11:78.CrossRef Olia J, Ansari M, Yaghmaei P, Ayatollahi H, Khalkhali H. Genotyping the human papillomavirus Infection in Iranian women referred to Shahid Motahari Hospital, in Urmia, with real-time polymerase chain reaction techniques. Annals of Tropical Medicine and Public Health. 2018;11:78.CrossRef
23.
go back to reference Mboumba Bouassa RS, Nodjikouambaye ZA, Sadjoli D, Adawaye C, Péré H, Veyer D, et al. High prevalence of cervical high-risk human papillomavirus Infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N’Djamena, Chad. PLoS ONE. 2019;14(6):e0217486.CrossRefPubMedPubMedCentral Mboumba Bouassa RS, Nodjikouambaye ZA, Sadjoli D, Adawaye C, Péré H, Veyer D, et al. High prevalence of cervical high-risk human papillomavirus Infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N’Djamena, Chad. PLoS ONE. 2019;14(6):e0217486.CrossRefPubMedPubMedCentral
24.
go back to reference Ghobadi M, Bashi Zadeh Fakhar H, Shaghaghi B. The prevalence of human papillomavirus genotypes in women with genital warts using polymerase chain reaction (PCR). Int J Cancer Manage. 2023;16(1). Ghobadi M, Bashi Zadeh Fakhar H, Shaghaghi B. The prevalence of human papillomavirus genotypes in women with genital warts using polymerase chain reaction (PCR). Int J Cancer Manage. 2023;16(1).
25.
go back to reference Zheng Y, Yu Q, Lin Y, Zhou Y, Lan L, Yang S, Wu J. Global burden and trends of sexually transmitted Infections from 1990 to 2019: an observational trend study. Lancet Infect Dis. 2022;22(4):541–51.CrossRefPubMed Zheng Y, Yu Q, Lin Y, Zhou Y, Lan L, Yang S, Wu J. Global burden and trends of sexually transmitted Infections from 1990 to 2019: an observational trend study. Lancet Infect Dis. 2022;22(4):541–51.CrossRefPubMed
26.
go back to reference Ciccarese G, Herzum A, Pastorino A, Dezzana M, Casazza S, Mavilia MG, et al. Prevalence of genital HPV Infection in STI and healthy populations and risk factors for viral persistence. Eur J Clin Microbiol Infect Dis. 2021;40(4):885–8.CrossRefPubMed Ciccarese G, Herzum A, Pastorino A, Dezzana M, Casazza S, Mavilia MG, et al. Prevalence of genital HPV Infection in STI and healthy populations and risk factors for viral persistence. Eur J Clin Microbiol Infect Dis. 2021;40(4):885–8.CrossRefPubMed
27.
go back to reference Amadane M, de Pree C, Viviano M, Vassilakos P, Jeannot E, Petignat P. Characteristics of HPV-unvaccinated undergraduate health students in Switzerland, a cross sectional study. Archives of Public Health. 2019;77(1):29.CrossRefPubMedPubMedCentral Amadane M, de Pree C, Viviano M, Vassilakos P, Jeannot E, Petignat P. Characteristics of HPV-unvaccinated undergraduate health students in Switzerland, a cross sectional study. Archives of Public Health. 2019;77(1):29.CrossRefPubMedPubMedCentral
28.
go back to reference Osazuwa-Peters N, Adjei Boakye E, Rohde RL, Ganesh RN, Moiyadi AS, Hussaini AS, Varvares MA. Understanding of risk factors for the human papillomavirus (HPV) Infection based on gender and race. Sci Rep. 2019;9(1):297.CrossRefPubMedPubMedCentral Osazuwa-Peters N, Adjei Boakye E, Rohde RL, Ganesh RN, Moiyadi AS, Hussaini AS, Varvares MA. Understanding of risk factors for the human papillomavirus (HPV) Infection based on gender and race. Sci Rep. 2019;9(1):297.CrossRefPubMedPubMedCentral
29.
go back to reference Machalek DA, Chow EPF, Garland SM, Wigan R, Cornall AM, Fairley CK, et al. Human papillomavirus prevalence in Unvaccinated Heterosexual Men after a National Female Vaccination Program. J Infect Dis. 2017;215(2):202–8.PubMed Machalek DA, Chow EPF, Garland SM, Wigan R, Cornall AM, Fairley CK, et al. Human papillomavirus prevalence in Unvaccinated Heterosexual Men after a National Female Vaccination Program. J Infect Dis. 2017;215(2):202–8.PubMed
Metadata
Title
Prevalence of high and low risk HPV genotypes among vaccinated and non-vaccinated people in Tehran
Authors
Amir Gholamzad
Niloofar Khakpour
Mehrdad Hashemi
Mehrdad Gholamzad
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2024
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02270-1

Other articles of this Issue 1/2024

Virology Journal 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine